Business Context and Reporting Period
This Form 8-K Current Report was filed by Alkermes Plc. (f/k/a Antler Science Two plc) on March 5, 2012, covering events occurring on February 29, 2012. The filing details the appointment of a new senior executive and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Base Salary: $350,000 annually for the new Senior Vice President, Chief Commercial Officer.
- Equity Grant: Option to purchase 100,000 Company shares, vesting ratably over four years (subject to Compensation Committee approval).
- Severance (Without Cause/Good Reason): 1x (Base Salary + Average Prior 2-Year Bonus) paid over 12 months, plus 12 months of health benefits.
- Change in Control Severance: 1.5x (Base Salary + Average Prior 2-Year Bonus) as a lump sum, plus pro rata bonus and 18 months of health benefits.
Material Changes
The primary material change is the appointment of Mark P. Stejbach as Senior Vice President, Chief Commercial Officer of Alkermes Inc., a wholly-owned indirect subsidiary of the Company. This appointment is effective as of February 29, 2012.
Outlook, Risks, and Unusual Items
Management Commentary: The filing outlines standard executive employment terms, including confidentiality obligations and non-solicitation restrictions for six months post-employment. Mr. Stejbach is eligible to participate in the company reporting officer performance pay plan for the fiscal year beginning April 1, 2012, pending plan adoption.
Risks and Contingencies: The agreement includes specific provisions for termination without cause, termination for "good reason" (e.g., material diminution in responsibilities), and change in control scenarios. The agreement explicitly states there is no "gross-up payment" for excise taxes on change in control severance.
Indemnification: Mr. Stejbach is entitled to enter into a deed of indemnification, where the Company will indemnify him to the maximum extent permitted by law for expenses incurred in relation to claims arising from his actions as an executive officer.
Investor Verification Checklist
- Verify the final approval of the 100,000 share option grant by the Compensation Committee.
- Confirm the adoption of the performance pay plan for the fiscal year beginning April 1, 2012.
- Review the specific definitions of "good reason" and "change in control" in the attached Exhibit 10.1 Employment Agreement.
- Monitor future filings for the execution of the Deed of Indemnification referenced in the report.